Unravel Health has raised $3.3M in Series A funding to bring its at-home hormone monitoring device closer to market. The company's device measures multiple hormones in saliva in near real time, aiming to reveal patterns that standard blood tests miss.
The round drew backing from Conduit EIS Impact Fund, Wrightwood, Leo Capital, Embryo Ventures, Hermesa, and Zinc VC. Unravel Health is building toward a future where individuals can track and understand their hormonal health from home, rather than relying on intermittent lab draws.
